Table 1 Distribution of SARS-CoV-2-specific antibodies detection in COVID-19 patients
From: Detection of SARS-CoV-2-specific antibodies via rapid diagnostic immunoassays in COVID-19 patients
Week | Positives (%) | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Asymptomatic | Symptomatic | ||||||||||||
Total | RDT | CMIA | ELISA | RTD | CMIA | ELISA | |||||||
IgM | IgG | IgM/IgG | IgG | IgG | IgA | IgM | IgG | IgM/IgG | IgG | IgG | IgA | ||
1 | 16 | 4/8 (50.0) | 6/8 (75.0) | 6/8 (75.0) | 6/8 (75.0) | 6/8 (75.0) | 6/8 (75.0) | 2/8 (25.0) | 1/8 (12.5) | 2/8 (25.0) | 1/8 (12.5) | 0/8 (0.0) | 0/8 (0.0) |
2 | 17 | 5/10 (50.0) | 6/10 (60.0) | 6/10 (60.0) | 8/10 (80.0) | 3/10 (30.0) | 9/10 (90.0) | 4/7 (57.1) | 3/7 (42.9) | 5/7 (71.4) | 4/7 (57.1) | 2/7 (28.6) | 4/7 (57.1) |
3 | 12 | 3/4 (75.0) | 4/4 (100.0) | 4/4 (100.0) | 4/4 (100.0) | 4/4 (100.0) | 4/4 (100.0) | 8/8 (100.0) | 8/8 (100.0) | 8/8 (100.0) | 8/8 (100.0) | 6/8 (75.0) | 8/8 (100.0) |
4 | 3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3/3 (100.0) | 3/3 (100.0) | 3/3 (100.0) | 3/3 (100.0) | 3/3 (100.0) | 3/3 (100.0) |
5 | 13 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 11/13 (84.6) | 11/13 (84.6) | 11/13 (84.6) | 12/13 (92.3) | 10/13 (76.9) | 11/13 (84.6) |
6 | 33 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 22/33 (66.7) | 28/33 (84.8) | 28/33 (84.8) | 27/33 (81.8) | 25/33 (75.8) | 25/33 (75.8) |
7 | 46 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 35/46 (76.1) | 41/46 (89.1) | 41/46 (89.1) | 40/46 (87.0) | 41/46 (89.1) | 40/46 (87.0) |
8 | 105 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 70/105 (66.7) | 87/105 (82.9) | 90/105 (85.7) | 85/105 (81.0) | 89/105 (84.8) | 86/105 (81.9) |
Total | 245 | 12/22 (54.5) | 16/22 (72.7) | 16/22 (72.7) | 18/22 (81.8) | 13/22 (59.1) | 19/22 (86.4) | 155/223 (69.5) | 182/223 (81.6) | 188/223 (84.3) | 180/223 (80.7) | 176/223 (78.9) | 177/223 (79.4) |